Cargando…

Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors

The aim of the present study was to evaluate the clinical utility of plasma chromogranin A (CgA) in patients diagnosed with early-stage pancreatic neuroendocrine tumors (PNETs) in terms of diagnostic value and treatment response. A total of 35 patients with PNETs were prospectively enrolled from Aug...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Chao-Ming, Cheng, Tsu-Yao, Chen, Tai-Been, Tien, Yu-Wen, Chen, Chien-Chuan, Lin, Jaw-Town, Wang, Hsiu-Po
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958764/
https://www.ncbi.nlm.nih.gov/pubmed/29805630
http://dx.doi.org/10.3892/ol.2018.8472
_version_ 1783324289740570624
author Tseng, Chao-Ming
Cheng, Tsu-Yao
Chen, Tai-Been
Tien, Yu-Wen
Chen, Chien-Chuan
Lin, Jaw-Town
Wang, Hsiu-Po
author_facet Tseng, Chao-Ming
Cheng, Tsu-Yao
Chen, Tai-Been
Tien, Yu-Wen
Chen, Chien-Chuan
Lin, Jaw-Town
Wang, Hsiu-Po
author_sort Tseng, Chao-Ming
collection PubMed
description The aim of the present study was to evaluate the clinical utility of plasma chromogranin A (CgA) in patients diagnosed with early-stage pancreatic neuroendocrine tumors (PNETs) in terms of diagnostic value and treatment response. A total of 35 patients with PNETs were prospectively enrolled from August 2010 to April 2014. Demographic and clinicopathological data were collected, and serial plasma CgA levels were measured. Tumor responses were defined by the Response Evaluation Criteria In Solid Tumors criteria. Pearson's χ2 test was used for the analysis of the association between the plasma CgA level and various factors. Plasma CgA level was significantly associated with the size (P=0.03), metastasis (P=0.02) and tumor stage (P=0.03) of the PNETs. Using 126 U/l as the optimal cutoff value, the sensitivity and specificity were 87.5 and 81.5%, respectively. For localized tumors, the sensitivity of CgA for diagnosing PNETs was relatively low, even following a lowering of the cutoff values (29.6–51.9%). Plasma CgA level was correlated with therapeutic response in those patients with high baseline CgA levels (P=0.025), but not in the patients with low baseline CgA levels (P=0.587). In conclusion, plasma CgA level was associated with tumor size, metastasis and tumor stage in patients with PNET. For early-stage PNETs, CgA exhibited a limited role in diagnosis and treatment response evaluation in the population of the present study.
format Online
Article
Text
id pubmed-5958764
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-59587642018-05-27 Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors Tseng, Chao-Ming Cheng, Tsu-Yao Chen, Tai-Been Tien, Yu-Wen Chen, Chien-Chuan Lin, Jaw-Town Wang, Hsiu-Po Oncol Lett Articles The aim of the present study was to evaluate the clinical utility of plasma chromogranin A (CgA) in patients diagnosed with early-stage pancreatic neuroendocrine tumors (PNETs) in terms of diagnostic value and treatment response. A total of 35 patients with PNETs were prospectively enrolled from August 2010 to April 2014. Demographic and clinicopathological data were collected, and serial plasma CgA levels were measured. Tumor responses were defined by the Response Evaluation Criteria In Solid Tumors criteria. Pearson's χ2 test was used for the analysis of the association between the plasma CgA level and various factors. Plasma CgA level was significantly associated with the size (P=0.03), metastasis (P=0.02) and tumor stage (P=0.03) of the PNETs. Using 126 U/l as the optimal cutoff value, the sensitivity and specificity were 87.5 and 81.5%, respectively. For localized tumors, the sensitivity of CgA for diagnosing PNETs was relatively low, even following a lowering of the cutoff values (29.6–51.9%). Plasma CgA level was correlated with therapeutic response in those patients with high baseline CgA levels (P=0.025), but not in the patients with low baseline CgA levels (P=0.587). In conclusion, plasma CgA level was associated with tumor size, metastasis and tumor stage in patients with PNET. For early-stage PNETs, CgA exhibited a limited role in diagnosis and treatment response evaluation in the population of the present study. D.A. Spandidos 2018-06 2018-04-12 /pmc/articles/PMC5958764/ /pubmed/29805630 http://dx.doi.org/10.3892/ol.2018.8472 Text en Copyright: © Tseng et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Tseng, Chao-Ming
Cheng, Tsu-Yao
Chen, Tai-Been
Tien, Yu-Wen
Chen, Chien-Chuan
Lin, Jaw-Town
Wang, Hsiu-Po
Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors
title Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors
title_full Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors
title_fullStr Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors
title_full_unstemmed Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors
title_short Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors
title_sort low accuracy of chromogranin a for diagnosing early-stage pancreatic neuroendocrine tumors
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958764/
https://www.ncbi.nlm.nih.gov/pubmed/29805630
http://dx.doi.org/10.3892/ol.2018.8472
work_keys_str_mv AT tsengchaoming lowaccuracyofchromograninafordiagnosingearlystagepancreaticneuroendocrinetumors
AT chengtsuyao lowaccuracyofchromograninafordiagnosingearlystagepancreaticneuroendocrinetumors
AT chentaibeen lowaccuracyofchromograninafordiagnosingearlystagepancreaticneuroendocrinetumors
AT tienyuwen lowaccuracyofchromograninafordiagnosingearlystagepancreaticneuroendocrinetumors
AT chenchienchuan lowaccuracyofchromograninafordiagnosingearlystagepancreaticneuroendocrinetumors
AT linjawtown lowaccuracyofchromograninafordiagnosingearlystagepancreaticneuroendocrinetumors
AT wanghsiupo lowaccuracyofchromograninafordiagnosingearlystagepancreaticneuroendocrinetumors